Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis
Preliminary evidence suggests that inhibition of dipeptidyl peptidase (DPP)-IV preserves pancreatic beta cell function in patients with type 2 diabetes (T2D). However, its effects on liver histology in nonalcoholic steatohepatitis (NASH), hepatic complication of diabetes, have not yet been adequatel...
Gespeichert in:
| Veröffentlicht in: | Acta gastro-enterologica belgica 2012-06, Vol.75 (2), p.240-244 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 244 |
|---|---|
| container_issue | 2 |
| container_start_page | 240 |
| container_title | Acta gastro-enterologica belgica |
| container_volume | 75 |
| creator | YILMAZ, Yusuf YONAL, Oya DEYNELI, Oguzhan ATAIZI CELIKEL, Cigdem KALAYCI, Cem GUNEY DUMAN, Deniz |
| description | Preliminary evidence suggests that inhibition of dipeptidyl peptidase (DPP)-IV preserves pancreatic beta cell function in patients with type 2 diabetes (T2D). However, its effects on liver histology in nonalcoholic steatohepatitis (NASH), hepatic complication of diabetes, have not yet been adequately explored. The present open-label, single-arm observational pilot study investigated the effects of one year of treatment with a dipeptidyl peptidase-IV inhibitor, sitagliptin, on liver histology, body mass index (BMI), and laboratory parameters in NASH patients with T2D.
Paired liver biopsies from 15 diabetic patients with NASH (7 males, 8 females; mean age: 49.7 +/- 8.1 years (range: 36-62)) before and after one year of therapy with sitagliptin 100 mg once daily were studied. Clinical and laboratory parameters were recorded.
Treatment with sitagliptin resulted in a significant decrease in ballooning (P = 0.014) and NASH scores (P = 0.04), while the reduction in the steatosis score was of borderline statistical significance (P = 0.054). These effects were accompanied by a significant reduction in body mass index, AST, and ALT levels.
Our study suggests that sitagliptin ameliorates liver enzymes and hepatocyte ballooning in NASH patients with T2D and may have therapeutic implications. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1032895705</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1032895705</sourcerecordid><originalsourceid>FETCH-LOGICAL-p171t-da9a41ae690e5697a319ec511b783b6ceba79a10f795ceb40a58df4cee4f65ae3</originalsourceid><addsrcrecordid>eNpF0E1LxDAQBuAcFHdZ9y9IL4KXQpI2TXOUZf2AFS96LtN0YiNpU5sU8d8bseIwMAzzMIf3jGyZrMu84FxuyD6Ed5pKlYxyekE2nNeSSkW35OloDOoYMm-yYCO8OTtFO2apOwstRquzCaLFMZlPG_ts9CM47Xvv0ilEhOh7_CHRhktybsAF3K9zR17vji-Hh_z0fP94uD3lE5Ms5h0oKBlgpSiKSkkomEItGGtlXbSVxhakAkaNVCItJQVRd6bUiKWpBGCxIze_f6fZfywYYjPYoNE5GNEvoWG04LUSkopEr1a6tAN2zTTbAeav5i-CBK5XAEGDMzOM2oZ_V6XYqJLFN_QrZfY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1032895705</pqid></control><display><type>article</type><title>Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>YILMAZ, Yusuf ; YONAL, Oya ; DEYNELI, Oguzhan ; ATAIZI CELIKEL, Cigdem ; KALAYCI, Cem ; GUNEY DUMAN, Deniz</creator><creatorcontrib>YILMAZ, Yusuf ; YONAL, Oya ; DEYNELI, Oguzhan ; ATAIZI CELIKEL, Cigdem ; KALAYCI, Cem ; GUNEY DUMAN, Deniz</creatorcontrib><description>Preliminary evidence suggests that inhibition of dipeptidyl peptidase (DPP)-IV preserves pancreatic beta cell function in patients with type 2 diabetes (T2D). However, its effects on liver histology in nonalcoholic steatohepatitis (NASH), hepatic complication of diabetes, have not yet been adequately explored. The present open-label, single-arm observational pilot study investigated the effects of one year of treatment with a dipeptidyl peptidase-IV inhibitor, sitagliptin, on liver histology, body mass index (BMI), and laboratory parameters in NASH patients with T2D.
Paired liver biopsies from 15 diabetic patients with NASH (7 males, 8 females; mean age: 49.7 +/- 8.1 years (range: 36-62)) before and after one year of therapy with sitagliptin 100 mg once daily were studied. Clinical and laboratory parameters were recorded.
Treatment with sitagliptin resulted in a significant decrease in ballooning (P = 0.014) and NASH scores (P = 0.04), while the reduction in the steatosis score was of borderline statistical significance (P = 0.054). These effects were accompanied by a significant reduction in body mass index, AST, and ALT levels.
Our study suggests that sitagliptin ameliorates liver enzymes and hepatocyte ballooning in NASH patients with T2D and may have therapeutic implications.</description><identifier>ISSN: 1784-3227</identifier><identifier>PMID: 22870790</identifier><language>eng</language><publisher>Brussels: Société Royale Belge de Gastro-Entérologie</publisher><subject>Adult ; Biological and medical sciences ; Body Mass Index ; Diabetes Mellitus, Type 2 - complications ; Diabetes. Impaired glucose tolerance ; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Fatty Liver - complications ; Fatty Liver - drug therapy ; Fatty Liver - pathology ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; Hepatocytes - drug effects ; Hepatocytes - pathology ; Humans ; Male ; Medical sciences ; Middle Aged ; Pilot Projects ; Pyrazines - therapeutic use ; Sitagliptin Phosphate ; Triazoles - therapeutic use</subject><ispartof>Acta gastro-enterologica belgica, 2012-06, Vol.75 (2), p.240-244</ispartof><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26094097$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22870790$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>YILMAZ, Yusuf</creatorcontrib><creatorcontrib>YONAL, Oya</creatorcontrib><creatorcontrib>DEYNELI, Oguzhan</creatorcontrib><creatorcontrib>ATAIZI CELIKEL, Cigdem</creatorcontrib><creatorcontrib>KALAYCI, Cem</creatorcontrib><creatorcontrib>GUNEY DUMAN, Deniz</creatorcontrib><title>Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis</title><title>Acta gastro-enterologica belgica</title><addtitle>Acta Gastroenterol Belg</addtitle><description>Preliminary evidence suggests that inhibition of dipeptidyl peptidase (DPP)-IV preserves pancreatic beta cell function in patients with type 2 diabetes (T2D). However, its effects on liver histology in nonalcoholic steatohepatitis (NASH), hepatic complication of diabetes, have not yet been adequately explored. The present open-label, single-arm observational pilot study investigated the effects of one year of treatment with a dipeptidyl peptidase-IV inhibitor, sitagliptin, on liver histology, body mass index (BMI), and laboratory parameters in NASH patients with T2D.
Paired liver biopsies from 15 diabetic patients with NASH (7 males, 8 females; mean age: 49.7 +/- 8.1 years (range: 36-62)) before and after one year of therapy with sitagliptin 100 mg once daily were studied. Clinical and laboratory parameters were recorded.
Treatment with sitagliptin resulted in a significant decrease in ballooning (P = 0.014) and NASH scores (P = 0.04), while the reduction in the steatosis score was of borderline statistical significance (P = 0.054). These effects were accompanied by a significant reduction in body mass index, AST, and ALT levels.
Our study suggests that sitagliptin ameliorates liver enzymes and hepatocyte ballooning in NASH patients with T2D and may have therapeutic implications.</description><subject>Adult</subject><subject>Biological and medical sciences</subject><subject>Body Mass Index</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - therapeutic use</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Fatty Liver - complications</subject><subject>Fatty Liver - drug therapy</subject><subject>Fatty Liver - pathology</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Hepatocytes - drug effects</subject><subject>Hepatocytes - pathology</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pilot Projects</subject><subject>Pyrazines - therapeutic use</subject><subject>Sitagliptin Phosphate</subject><subject>Triazoles - therapeutic use</subject><issn>1784-3227</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpF0E1LxDAQBuAcFHdZ9y9IL4KXQpI2TXOUZf2AFS96LtN0YiNpU5sU8d8bseIwMAzzMIf3jGyZrMu84FxuyD6Ed5pKlYxyekE2nNeSSkW35OloDOoYMm-yYCO8OTtFO2apOwstRquzCaLFMZlPG_ts9CM47Xvv0ilEhOh7_CHRhktybsAF3K9zR17vji-Hh_z0fP94uD3lE5Ms5h0oKBlgpSiKSkkomEItGGtlXbSVxhakAkaNVCItJQVRd6bUiKWpBGCxIze_f6fZfywYYjPYoNE5GNEvoWG04LUSkopEr1a6tAN2zTTbAeav5i-CBK5XAEGDMzOM2oZ_V6XYqJLFN_QrZfY</recordid><startdate>20120601</startdate><enddate>20120601</enddate><creator>YILMAZ, Yusuf</creator><creator>YONAL, Oya</creator><creator>DEYNELI, Oguzhan</creator><creator>ATAIZI CELIKEL, Cigdem</creator><creator>KALAYCI, Cem</creator><creator>GUNEY DUMAN, Deniz</creator><general>Société Royale Belge de Gastro-Entérologie</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20120601</creationdate><title>Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis</title><author>YILMAZ, Yusuf ; YONAL, Oya ; DEYNELI, Oguzhan ; ATAIZI CELIKEL, Cigdem ; KALAYCI, Cem ; GUNEY DUMAN, Deniz</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p171t-da9a41ae690e5697a319ec511b783b6ceba79a10f795ceb40a58df4cee4f65ae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Biological and medical sciences</topic><topic>Body Mass Index</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - therapeutic use</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Fatty Liver - complications</topic><topic>Fatty Liver - drug therapy</topic><topic>Fatty Liver - pathology</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Hepatocytes - drug effects</topic><topic>Hepatocytes - pathology</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pilot Projects</topic><topic>Pyrazines - therapeutic use</topic><topic>Sitagliptin Phosphate</topic><topic>Triazoles - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>YILMAZ, Yusuf</creatorcontrib><creatorcontrib>YONAL, Oya</creatorcontrib><creatorcontrib>DEYNELI, Oguzhan</creatorcontrib><creatorcontrib>ATAIZI CELIKEL, Cigdem</creatorcontrib><creatorcontrib>KALAYCI, Cem</creatorcontrib><creatorcontrib>GUNEY DUMAN, Deniz</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Acta gastro-enterologica belgica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>YILMAZ, Yusuf</au><au>YONAL, Oya</au><au>DEYNELI, Oguzhan</au><au>ATAIZI CELIKEL, Cigdem</au><au>KALAYCI, Cem</au><au>GUNEY DUMAN, Deniz</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis</atitle><jtitle>Acta gastro-enterologica belgica</jtitle><addtitle>Acta Gastroenterol Belg</addtitle><date>2012-06-01</date><risdate>2012</risdate><volume>75</volume><issue>2</issue><spage>240</spage><epage>244</epage><pages>240-244</pages><issn>1784-3227</issn><abstract>Preliminary evidence suggests that inhibition of dipeptidyl peptidase (DPP)-IV preserves pancreatic beta cell function in patients with type 2 diabetes (T2D). However, its effects on liver histology in nonalcoholic steatohepatitis (NASH), hepatic complication of diabetes, have not yet been adequately explored. The present open-label, single-arm observational pilot study investigated the effects of one year of treatment with a dipeptidyl peptidase-IV inhibitor, sitagliptin, on liver histology, body mass index (BMI), and laboratory parameters in NASH patients with T2D.
Paired liver biopsies from 15 diabetic patients with NASH (7 males, 8 females; mean age: 49.7 +/- 8.1 years (range: 36-62)) before and after one year of therapy with sitagliptin 100 mg once daily were studied. Clinical and laboratory parameters were recorded.
Treatment with sitagliptin resulted in a significant decrease in ballooning (P = 0.014) and NASH scores (P = 0.04), while the reduction in the steatosis score was of borderline statistical significance (P = 0.054). These effects were accompanied by a significant reduction in body mass index, AST, and ALT levels.
Our study suggests that sitagliptin ameliorates liver enzymes and hepatocyte ballooning in NASH patients with T2D and may have therapeutic implications.</abstract><cop>Brussels</cop><pub>Société Royale Belge de Gastro-Entérologie</pub><pmid>22870790</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1784-3227 |
| ispartof | Acta gastro-enterologica belgica, 2012-06, Vol.75 (2), p.240-244 |
| issn | 1784-3227 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1032895705 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Biological and medical sciences Body Mass Index Diabetes Mellitus, Type 2 - complications Diabetes. Impaired glucose tolerance Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Fatty Liver - complications Fatty Liver - drug therapy Fatty Liver - pathology Female Gastroenterology. Liver. Pancreas. Abdomen Hepatocytes - drug effects Hepatocytes - pathology Humans Male Medical sciences Middle Aged Pilot Projects Pyrazines - therapeutic use Sitagliptin Phosphate Triazoles - therapeutic use |
| title | Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T22%3A22%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20sitagliptin%20in%20diabetic%20patients%20with%20nonalcoholic%20steatohepatitis&rft.jtitle=Acta%20gastro-enterologica%20belgica&rft.au=YILMAZ,%20Yusuf&rft.date=2012-06-01&rft.volume=75&rft.issue=2&rft.spage=240&rft.epage=244&rft.pages=240-244&rft.issn=1784-3227&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1032895705%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1032895705&rft_id=info:pmid/22870790&rfr_iscdi=true |